Drug intelligence / Profile preview

DWC202202

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical

Overview

DWC202202 is an investigational drug developed by Daewoong. It has been studied in phase 1 clinical trials, primarily to evaluate its pharmacodynamic and pharmacokinetic interactions with other drugs such as DWP14012 in healthy volunteers. The specific mechanism of action for DWC202202 is currently unknown, and there are no approved indications or known adverse events reported for this compound. Limited information is available regarding its therapeutic class, molecular modality, or target diseases beyond early-phase safety studies[3][2][1].

Other names: DWC202202DWC-202202DWC 202202

Beyond the preview

Go deeper on DWC202202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202202.

Explore the full profile